The News
Catch the latest updates as CTMC drives innovation in cell therapy to accelerate development and manufacturing
to impact patients sooner
Press Releases
Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
HOUSTON, Texas, Dec 19, 2022 – Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today...
Ori Biotech and CTMC partner to accelerate novel cell therapy delivery
London, UK, and Houston, TX, US, September 13, 2022 - Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technologies, and the...
MD Anderson and Obsidian Therapeutics announce FDA clearance of IND application for novel TIL therapy OBX-115
HOUSTON and CAMBRIDGE, Mass. ― The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug...
Recent News
APAC is dynamic and rapidly evolving, with tremendous growth in R&D and attractive market conditions
| Opinion | By Dr Manbeena Chawla With cell and gene therapy (CGT) representing a major advancement in medical...
Inside CTMC: Innovating cell therapy development from patient to clinic
Cell therapy has emerged as one of the most promising frontiers in biopharmaceutical innovation, offering potential cures for diseases once...
Houston’s Biotech Ecosystem: The Ideal Launchpad for Life Sciences Startups
Access Greater Houston Partnership's blog: GHP
CAR T-Cell Therapy: New Advances Move On Past Setbacks
Ongoing efforts to go from “liquid” to “solid” tissues are starting to pay off in multiple diseases Access the article: GEN news
Expert tips to choose the right CDMO for your biotech company
By Jules Adam Outsourcing to a contract development and manufacturing organization (CDMO) is a critical step for many biotech companies aiming...
3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization
By Amy Hay, CBO, CTMC Cell and gene therapies have introduced unprecedented therapeutic possibilities into the clinical landscape, but their...
Emerging Treatments for Cancer e-book
Access article: BioPharm International
TILs’ Tomorrow Bringing More Cancers Under Immune Control
Four leading companies prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities...
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies.
Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO® platform combining best-in-class technology with...